Literature DB >> 6288725

3,4-bis(3'-hydroxyphenyl)hexane--a new mammary tumor-inhibiting compound. Studies on the mechanism of action on the DMBA-induced, hormone-dependent mammary tumor of the rat.

R W Hartmann, H Schönenberger, K H Wrobel.   

Abstract

Biochemical properties, such as the activities of eight carbohydrate-metabolism-linked enzymes and four acid hydrolases, and histological characteristics of growing and regressing DMBA-induced mammary tumors of the SD-rat after ovariectomy or treatment of the host with hexesterol, tamoxifen, and 3,4-bis(3'-hydroxyphenyl)hexane were determined. Significant differences were found between growing and regressing tumors regardless of the treatment animals had been subjected to. Only few differences in biochemical parameters could be found within the group of tumors regressing due to the applied therapy. The histological signs of regressing tumors were very diverse, but no phenomenon typical of a specific treatment could be found. It cannot be decided whether the partial antiestrogen, 3,4-bis(3'-hydroxyphenyl)hexane unfolds its antimammary tumor activity by means of its estrogenic or its antiestrogenic potency. The hypothesis that estrogens inhibit mammary tumor growth by directing neoplastic cell metabolism toward secretion is not supported by these findings.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6288725     DOI: 10.1007/bf00409700

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  33 in total

1.  EFFECTS OF DIET AND INSULIN ON GLUCOSE-ADENOSINE TRIPHOSPHATE PHOSPHOTRANSFERASES OF RAT LIVER.

Authors:  C SHARMA; R MANJESHWAR; S WEINHOUSE
Journal:  J Biol Chem       Date:  1963-12       Impact factor: 5.157

2.  The effect of antiestrogens on egg yolk protein synthesis and estrogen-binding to chromatin in the rooster liver.

Authors:  M Gschwendt
Journal:  Biochim Biophys Acta       Date:  1975-08-13

3.  Cyclic adenosine 3',5'-monophosphate-binding protein: role in ovariectomy-induced regression of a hormone-dependent mammary tumor in Sprague-Dawley female rats.

Authors:  Y S Cho-Chung; J S Bodwin; T Clair
Journal:  J Natl Cancer Inst       Date:  1978-05       Impact factor: 13.506

4.  Lysosomal enzyme activation in irradiated mammary tumors.

Authors:  C Clarke; E D Wills
Journal:  Radiat Res       Date:  1976-09       Impact factor: 2.841

5.  Some biochemical changes preceding regression of 7,12-dimethylbenz(a)anthracene-induced mammary tumors following oophorectomy.

Authors:  R Hilf; J W Battaglini; J A Delmez; N Cohen; W D Rector
Journal:  Cancer Res       Date:  1971-09       Impact factor: 12.701

6.  Mammary tumor regression. V. Role of acid ribonuclease and cathepsin.

Authors:  Y S Cho-Chung; P M Gullino
Journal:  J Biol Chem       Date:  1973-07-10       Impact factor: 5.157

7.  Studies on mammary gland involution. I. On the ultrastructure of the lactating mammary gland.

Authors:  H J Helminen; J L Ericsson
Journal:  J Ultrastruct Res       Date:  1968-11

8.  Quantitation of cell shedding into efferent blood of mammary adenocarcinoma.

Authors:  T P Butler; P M Gullino
Journal:  Cancer Res       Date:  1975-03       Impact factor: 12.701

9.  3,4-bis(3'-hydroxyphenyl)hexane--a new mammary tumor-inhibiting compound.

Authors:  G Kranzfelder; R W Hartmann; E von Angerer; H Schönenberger; A E Bogden
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

10.  Influence of diethylstilbestrol (DES) on reticuloendothelial function, tissue distribution, and detoxication of S. enteritidis endotoxin.

Authors:  R A Trejo; L D Loose; N R Di Luzio
Journal:  J Reticuloendothel Soc       Date:  1972-01
View more
  1 in total

1.  [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II), a new drug not only parenterally but also orally active in the therapy of breast and prostate cancer.

Authors:  T Spruss; S Schertl; M R Schneider; R Gust; K Bauer; H Schönenberger
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.